Aurora Analytica Appoints Håkon Thomas Olsen to Advisory Board
Oslo, Norway – 3rd September 2025 – Aurora Analytica, a leading healthcare analytics company transforming clinical trial design through advanced data and AI, is pleased to announce the appointment of Håkon Thomas Olsen to its Advisory Board.
Håkon brings extensive expertise in commercial strategy, business development, and financial leadership, gained from senior roles across multiple industries. He currently leads financial and strategic work at Optime Subsea, where he also as served as the Chief Commercial Officer. Earlier he as held positions including Vice President of Business Development at Quantafuel and Sales & Business Development Director in TFMC. Håkon has also co-founded Klokk & Co and served on several boards, providing deep experience in corporate strategy, investment assessment, and growth initiatives.
“We are thrilled to welcome Håkon to our Advisory Board,” said Bhavish Lekh, CEO of Aurora Analytica. “His commercial insight, financial acumen, and strategic experience will be invaluable as we scale our platform and drive growth in the clinical trial optimization space.”
In his advisory role, Håkon will support Aurora Analytica in shaping business strategy, guiding commercial partnerships, and advising on investment and financial planning to accelerate the company’s growth.
About Aurora Analytica
Aurora Analytica is a pioneering healthcare analytics company committed to transforming clinical trial design through advanced AI-driven insights. Its Aurora Suite platform enables faster, more accurate, and cost-efficient clinical trial strategies, ultimately accelerating the delivery of new therapies to patients.
